Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company, has announced a definitive agreement for the purchase and sale of 2,857,144 shares of its common stock at an offering price of $0.70 per share. This registered direct offering is expected to generate approximately $2 million in gross proceeds before deducting placement agent fees and other expenses. The offering is being conducted under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on December 4, 2025. In conjunction with this offering, Hoth Therapeutics is also issuing unregistered warrants to purchase an aggregate of 2,857,144 shares of common stock at an exercise price of $0.85 per share. These warrants will become exercisable six months after issuance and will expire five and a half years thereafter. The company plans to use the net proceeds from the offering for general corporate purposes, including working capital. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering. The closing of the offering is anticipated to occur on or about April 2, 2026, subject to customary closing conditions.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.